Threshold Pharmaceuticals, Inc.
170 Harbor Way
Suite 300
South San Francisco
California
94080-6108
United States
Tel: 650-474-8200
Fax: 650-474-2529
Website: http://www.thresholdpharm.com/
Email: hr@thresholdpharm.com
269 articles about Threshold Pharmaceuticals, Inc.
-
Threshold Pharmaceuticals, Inc. Announces Update on Its Phase 3 Trial in Soft Tissue Sarcoma
7/1/2013
-
Threshold Pharmaceuticals, Inc. Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 American Society of Clinical Oncology Annual Meeting
6/3/2013
-
Threshold Pharmaceuticals, Inc. Announces Presentations and Webcasts at Three Upcoming Investor Conferences
5/10/2013
-
Threshold Pharmaceuticals, Inc. Reports First Quarter 2013 Financial and Operational Results
5/2/2013
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at the 12th Annual Needham Healthcare Conference
4/25/2013
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at the 20th Annual Future Leaders in the Biotech Industry Conference
4/1/2013
-
Threshold Pharmaceuticals, Inc. Announces Acquisition of Investigational Hypoxia PET Imaging Agent [18F]HX4 From Siemens Healthcare
3/21/2013
-
Threshold Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2012 Financial and Operational Results
3/7/2013
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at Cowen and Company's 33rd Annual Health Care Conference
2/26/2013
-
Threshold Pharmaceuticals, Inc. Higher as Phase 3 Moves Forward, Earns $30 Million Milestone Payment
1/25/2013
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at Oppenheimer 23rd Annual Healthcare Conference
12/10/2012
-
Threshold Pharmaceuticals, Inc. Reports Updated Phase 2 Results Including Analysis of Maintenance Therapy With TH-302 Following Induction Therapy With TH-302 Plus Doxorubicin in Soft Tissue Sarcoma
11/15/2012
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at Lazard Capital Markets 9th Annual Healthcare Conference
11/7/2012
-
Threshold Pharmaceuticals, Inc. Reports Third Quarter 2012 Financial and Operational Results
11/2/2012
-
FDA Reaches Agreement With Merck KGaA Affiliate, Threshold Pharmaceuticals, Inc. for TH-302
10/16/2012
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at 11th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/4/2012
-
Threshold Pharmaceuticals, Inc. Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
10/1/2012
-
Threshold Pharmaceuticals, Inc. Announces Presentations on TH-302 in Pancreatic Cancer and Glioblastoma at ESMO
9/26/2012
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at BIOX, Noble Financial Capital Markets' Life Sciences Exposition
9/19/2012
-
Threshold Pharmaceuticals, Inc. Announces Presentation and Webcast at UBS Global Life Sciences Conference
9/18/2012